- Home
- KOD vs RIGL Comparison
KOD vs RIGL Comparison
Compare KOD & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- RIGL
- Stock Information
- Founded
- KOD 2009
- RIGL 1996
- Country
- KOD United States
- RIGL United States
- Employees
- KOD N/A
- RIGL N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- KOD Health Care
- RIGL Health Care
- Exchange
- KOD Nasdaq
- RIGL Nasdaq
- Market Cap
- KOD 454.7M
- RIGL 486.4M
- IPO Year
- KOD 2018
- RIGL 2000
- Fundamental
- Price
- KOD $7.50
- RIGL $21.81
- Analyst Decision
- KOD Hold
- RIGL Buy
- Analyst Count
- KOD 4
- RIGL 5
- Target Price
- KOD $8.00
- RIGL $34.80
- AVG Volume (30 Days)
- KOD 448.1K
- RIGL 347.9K
- Earning Date
- KOD 11-14-2024
- RIGL 03-04-2025
- Dividend Yield
- KOD N/A
- RIGL N/A
- EPS Growth
- KOD N/A
- RIGL N/A
- EPS
- KOD N/A
- RIGL 0.22
- Revenue
- KOD N/A
- RIGL $157,374,000.00
- Revenue This Year
- KOD N/A
- RIGL $51.34
- Revenue Next Year
- KOD N/A
- RIGL $15.75
- P/E Ratio
- KOD N/A
- RIGL $98.50
- Revenue Growth
- KOD N/A
- RIGL 21.65
- 52 Week Low
- KOD $2.19
- RIGL $7.48
- 52 Week High
- KOD $11.60
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- KOD 44.49
- RIGL 64.53
- Support Level
- KOD $7.21
- RIGL $17.28
- Resistance Level
- KOD $9.14
- RIGL $18.25
- Average True Range (ATR)
- KOD 0.86
- RIGL 1.37
- MACD
- KOD -0.33
- RIGL 0.65
- Stochastic Oscillator
- KOD 15.73
- RIGL 99.68
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.